Integra LifeSciences Holdings(IART)
USD --+0.00%
Reward41Moderate
Risk66Medium-High
📊75%Data
Thin -30% profit margin
IART
+0.0 · +0.00%
USD · NASDAQ
Integra LifeSciences Holdings | Healthcare
Capital Destroyer
Market Cap:902.99M
ℹ️
Reward Rating
41
Moderate
Bottom 10% (model universe)
75% data coverage
ℹ️
Risk Rating
66
Medium-High
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on IART to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $15.50.

What is Integra LifeSciences Holdings?

Integra LifeSciences Holdings Corporation manufactures and sells surgical instrument, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology.

IART · Verdict

Moderate reward · elevated risk

IART has limited near-term tailwinds — balance sheet and growth weigh on the model output.

Based on 88% data coverage

IART · Verdict

What’s working & what to watch

Watchouts 4

  • Balance sheet13/100

    Interest covered 0.7×

  • Growth33/100

    Revenue +1.5% CAGR

  • Cash flow40/100

    2% free-cash-flow margin

  • Profitability42/100

    -0% net margin · -39% ROE

Model-based scoring. For information only — not financial advice.

What is Integra LifeSciences Holdings?

Integra LifeSciences Holdings Corporation manufactures and sells surgical instrument, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 902.99M.

Financial Highlights

Investment Breakdown

📈 Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
💰 Profitability
Profitability metrics are mixed — margins may be under pressure.
⚠️ Risk
Moderate volatility with meaningful macro and earnings sensitivity.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (41)

The scoring profile indicates limited reward potential at this time, with momentum and size offering the most support. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap902.99M
P/E RatioN/A
Dividend YieldN/A
52 Week High24.365
52 Week Low10.6
Last AnnualDecember
IPO Date8/16/1995
IncorporatedUSA
Shares Outstanding78M
No. of Employees4,396
IndustryMedical Devices
ExchangeNASDAQ
Beta1.031
CurrencyUSD